White Paper

Leveraging Efficiency From Cell Line Development To Clinical Manufacturing Of Monoclonal Antibodies

Source: Curia

By Norman Garceau, PhD, VP Global R&D and Technology; Jordon Wang, PhD, Vice President, Technology Development; Tyler Jones, PhD, Director, Formulation; Ranald Baillie, Vice President, Global R&D Drug Product; and Lisa Alexander, Vice President, Quality Operations, Curia

GettyImages-1133973085-monoclonal-antibody

Accelerate your biologic journey from discovery to clinical batches with a trusted CDMO boasting a comprehensive program tailored for a seamless transition. With the FDA witnessing a steady rise in approved monoclonal antibodies (mAbs), and late-stage developments increasing by over 30% from 2021 to 2022, the race to market dominance intensifies.

Biopharmaceutical firms recognize the pivotal advantage of being first to market and seek to compress the typical decade-long timeline from discovery to regulatory approval. At Curia, we excel in swiftly transitioning from rapid antibody discovery to GMP manufacturing of clinical phase drug substances, leveraging proprietary technology, innovative process engineering with single-use equipment, and rigorous quality control measures.

Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma